Renflexis, a Remicade Biosimilar, Launched in US to Treat Crohn’s and UC

Renflexis, a Remicade Biosimilar, Launched in US to Treat Crohn’s and UC
New drug Renflexis (infliximab-abda), a therapy for ulcerative colitis and Crohn’s disease, is being launched in the U.S., South Korea’s Samsung Bioepis recently announced. Renflexis is a biosimilar of the anti-inflammatory drug Remicade (infliximab) and is being commercialized in the U.S. by Merck. Biosimilars are therapies with no clinically relevant differences to a biological reference product previously approved

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

3 comments

  1. Donna Ellis says:

    Wish the FDA would approve fecal transplants for ulcerative colitis. Guess there is less of a money gain in that approach. I’m staying hopeful. It’s the way to help sufferers.

Leave a Comment

Your email address will not be published. Required fields are marked *